ESC 365 - Additional cholesterol synthesis inhibition, CETP inhibitors, and cholesterol-efflux enhancer therapies

ESC Professional Premium Access

Additional cholesterol synthesis inhibition, CETP inhibitors, and cholesterol-efflux enhancer therapies

Session: Targeting lipids above and beyond statins: key new players

Topic: Lipid-Lowering Agents

Speaker: Professor U. Landmesser (Berlin, DE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Ulf Landmesser

German Heart Centre Berlin, Berlin (Germany)

43 presentations

2 followers

4 more presentations in this session

PCSK9 inhibition: new insights

Speaker: Professor L. Raber (Bern, CH)

Strategies to inhibit Lp(a)

Speaker: Professor F. Kronenberg (Innsbruck, AT)

Targeting triglycerides: is it worth it? lessons from recent trials

Speaker: Associate Professor G. Liuzzo (Rome, IT)

Targeting lipids above and beyond statins: key new players - discussion

Access the full session

Targeting lipids above and beyond statins: key new players

Speakers: Professor U. Landmesser, Professor L. Raber, Professor F. Kronenberg, Associate Professor G. Liuzzo

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources